Proteomic Profiling of Triple-negative Breast Carcinomas in Combination With a Three-tier Orthogonal Technology Approach Identifies Mage-A4 as Potential Therapeutic Target in Estrogen Receptor Negative Breast Cancer*

Teresa Cabezon‡§§§, Irina Gromova‡§§§‡‡, Pavel Gromov‡§, Reza Serizawa§¶, Vera Timmermans Wielenga§¶, Niels Kroman/H20648, Julio E. Celis‡§, and Jose M. A. Moreira‡§**‡‡

Breast cancer is a very heterogeneous disease, encompassing several intrinsic subtypes with various morphological and molecular features, natural history and response to therapy. Currently, molecular targeted therapies are available for estrogen receptor (ER) and human epidermal growth factor receptor 2 (Her2)-positive breast tumors. However, a significant proportion of primary breast cancers are negative for ER, progesterone receptor (PgR), and Her2, comprising the triple negative breast cancer (TNBC) group. Women with TNBC have a poor prognosis because of the aggressive nature of these tumors and current lack of suitable targeted therapies. As a consequence, the identification of novel relevant protein targets for this group of patients is of great importance. Using a systematic two dimensional (2D) gel-based proteomic profiling strategy, applied to the analysis of fresh TNBC tissue biopsies, in combination with a three-tier orthogonal technology (two dimensional PAGE/silver staining coupled with MS, two dimensional Western blotting, and immunohistochemistry) approach, we aimed to identify targetable protein markers that were present in a significant fraction of samples and that could define therapy-amenable sub-groups of TNBCs. We present here our results, including a large cumulative database of proteins based on the analysis of 78 TNBCs, and the identification and validation of one specific protein, Mage-A4, which was expressed in a significant fraction of TNBC and Her2-positive/ER negative lesions. The high level expression of Mage-A4 in the tumors studied allowed the detection of the protein in the tumor interstitial fluids as well as in sera. The existence of immunotherapeutics approaches specifically targeting this protein, or Mage-A protein family members, and the fact that we were able to detect its presence in serum suggest novel management options for TNBC and human epidermal growth factor receptor 2 positive/estrogen receptor negative patients bearing Mage-A4 positive tumors.

Molecular & Cellular Proteomics 12: 10.1074/mcp.M112.019786, 381–394, 2013.

Breast cancer, although a very heterogeneous disease, can be divided into three therapeutically relevant fundamental disease entities, simply based on estrogen receptor (ER) and human epidermal growth factor receptor 2 (Her2) status (i.e. ER+ and/or Her2+, and ER−Her2−), as the major currently available breast cancer therapeutic options are based on the ability to target these proteins. Hormone receptor positive and hormone receptor negative breast cancers are disease entities with distinct morphological, genetic and biological behavior (1). Hormone receptor negative tumors, which constitute ~30% of primary breast cancers, tend to be high-grade, more frequently BRCA1 and TP53 mutated, and, more importantly, are not amenable to endocrine therapy. Her2 is amplified in ~18–20% of breast cancers, and is more frequently observed in hormone receptor negative tumors. Her2 amplification is associated with worse prognosis (higher rate of recurrence and mortality) in patients with newly diagnosed breast cancer who do not receive any adjuvant systemic therapy. Her2

* The abbreviations used are: Her2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; 2D PAGE, two-dimensional polyacrylamide gel electrophoresis; ER, estrogen receptor; PgR, progesterone receptor.

From the ‡Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, DK-2100, Copenhagen, Denmark; §Department of Translational Breast Cancer Research (DCTB), DK-2100, Copenhagen, Denmark; ¶Department of Pathology, the Centre of Diagnostic Investigations, Copenhagen University Hospital, DK-2100, Copenhagen, Denmark; ||Department of Breast Surgery, Copenhagen University Hospital, DK-2100, Copenhagen, Denmark; **Section of Pathobiology and Sino-Danish Breast Cancer Research Centre, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-1870, Frederiksberg

Received April 18, 2012, and in revised form, October 16, 2012
Published, MCP Papers in Press, November 21, 2012, DOI 10.1074/mcp.M112.019786

Molecular & Cellular Proteomics 12.2
status is also predictive for several systemic therapies, particularly for agents that target Her2. The development of a humazoned monoclonal antibody against Her2 (trastuzumab) has resulted in reduction of the risk of recurrence and mortality in patients with Her2 amplification (2, 3). Although trastuzumab is considered one of the most effective targeted therapies currently available in oncology, a significant number of patients with Her2-overexpressing breast cancer do not benefit from it (4, 5).

Breast tumors that do not express ER, PgR, or Her2 (ER− PgR− Her2−), as determined by immunohistochemistry (IHC), are generally referred to as triple negative breast cancers (TNBCs), and they are not candidates for targeted therapies (endocrine therapy or trastuzumab). Although TNBCs account for a relatively small proportion of breast cancer cases (10−15%), they are responsible for a disproportionate number of breast cancer deaths. TNBC tumors form a recognizable prognostic group of breast cancer with aggressive behavior that currently lacks the benefit of available systemic therapy (6−8). Given the need to develop molecular criteria to reproducibly categorize molecular breast tumor subtypes at the protein level and the lack of targeted therapies available to treat patients bearing TNBCs, we have implemented a systematic proteomics approach to identify, characterize, and evaluate proteins present in triple-negative tumors that could constitute an appropriate therapeutic target for the clinical management of this group of patients. To this end, based on the analysis of 78 individual TNBC samples, we have established a large, cumulative, 2D-PAGE database of proteins expressed by TNBCs, including some that could be of potential therapeutic value. Comparison of this TNBC protein database with protein databases of other breast cancer subtypes previously established by our laboratory allowed us to single out a number of proteins preferentially expressed in TNBCs for which targeted therapeutics exist. In this report we further focused on the characterization of one such target, the cancer/testis antigen, melanoma-associated antigen 4 - Mage-A4.

Cancer/testis antigens (CTAs) are expressed in a large variety of tumor types, whereas their expression in normal tissues is restricted to male germ cells, which are immune-privileged because of their lack of or low expression of human leukocyte antigen (HLA) molecules (9). Several studies have shown the existence of natural cellular and humoral responses against some CTAs, indicating that they are appropriate targets for vaccine-based cancer immunotherapy (10−12). So far, the use of CTAs in immunotherapeutic approaches to cancer treatment has been tested in more than 60 early phase clinical trials, with varying success, and a few candidate products have reached late-stage clinical trials. One such candidate vaccine, Astuprotimut-R (GSK-249553), a Mage-A3 antigen-specific cancer immunotherapeutic agent, is currently under clinical evaluation by GlaxoSmithKline in the largest-ever treatment trial in lung cancer, called MAGRIT.

(Mage-A3 as Adjuvants nonsmall cell lung cancer Immunotherapy) (13).

At present, CTAs comprise about 150 members, more than half of which are encoded by large, recently expanded families on chromosome X (14; see also CTDatabase at www.cataincbc.br; last accessed 01.09.2012). These genes are organized into clusters and have undergone rapid evolution, possibly because of positive selection. The biological functions of CTAs are not fully understood, but emerging evidence suggest that they direct the proliferation, differentiation, and survival of human germ line cells and may have similar effect in cancer cells. Mage-A4 protein belongs to the Mage-A family of CT antigens. The Mage-A family is composed by 12 proteins (14, 15) and many members of the Mage-A family of CTAs have been associated with cancer, including breast cancer (14, 16, 17). However, past studies reported mostly on MAGE genes rather than protein expression, or on the expression of Mage protein families and not on any given specific protein.

In this paper we describe the identification of Mage-A4 in breast tumor biopsies using 2D PAGE coupled with MS proteomics, and follow the protein localization from the tumor cells, to the tumor microenvironment, and to the serum of a patient. Using a three-tier orthogonal technology approach that combined 2D PAGE silver staining coupled with MS, with 2D Western blotting, and IHC, we showed that high level Mage-A4 expression in breast tumors occurs almost exclusively in the receptor negative disease (TNBC and Her2− ER− PgR−). The existence of immunotherapeutic approaches targeting MAGE protein family members (Mage-A4 specific or with broader specificity) and the fact that we were able to detect its presence in serum suggest novel management options for patients bearing Mage-A4 positive TNBCs and Her2− ER− PgR− tumors.

**EXPERIMENTAL PROCEDURES**

*Sample Collection and Handling—* Tissue and serum samples from clinical high-risk patients (high-risk definition according to the Danish Breast Cooperative Group; www.dbcg.dk, last accessed 22.10.2009) that underwent mastectomy between 2003 and 2008, were collected within the Danish Center for Translational Breast Cancer Research program. All patients had no previous surgery to the breast and did not receive preoperative treatment. They presented a unifocal tumor of an estimated size of more than 20 mm. In addition, 78 nonselected retrospective TNBCs and 30 Her2-positive cases were provided by the Department of Pathology at the Copenhagen University Hospital.

Fresh breast tissue samples for 2D PAGE were flash-frozen in liquid nitrogen following surgery and were rapidly transported to the Institute of Cancer Biology where they were stored at −80°C until the time of analysis; on average no more than 15 min elapsed from tissue excision to freezing. Samples for interstitial fluid recovery from tumors and normal specimens were kept in PBS at 4°C and were routinely prepared within a maximum of 30−45 min from the time of surgical excision. The project was approved (KF 01−069/03) by the Copenhagen and Frederiksberg regional division of the Danish National Committee on Biomedical Research Ethics. Tests samples were provided by the Department of Growth and Reproduction at the
Copenhagen University Hospital. Blood samples were drawn preoperatively into endotoxin-free collection tubes without anticoagulation agents and processed as soon as possible (no later than 1.5 h after collection). Samples were centrifuged at 2000 × g for 10 min to separate the plasma from blood cells, and stored frozen at −80 °C until analyzed.

**Sample Preparation for 2D PAGE**—Twenty to thirty, 6-μm cryostat sections of frozen tissues were resuspended in 0.1 ml lysis solution for 2D-PAGE (18, 19). The resulting lysates were frozen and kept at −20 °C until used, usually within 24–48 h. Twenty to forty microliters were applied to the gel tube for isoelectricfocusing (IEF) as described (19), and each sample was run at least in duplicate. The first and last two sections of each sample were used for hematoxylin and eosin (H&E) staining and immunofluorescence analysis using cytokeratin 19 (CK19) antibodies, respectively. The H&E stained sections were reviewed by a pathologist to do a coarse determination of the percentage of tumors in cells. In addition, we analyzed the tissue sections for CK19 positive cells, as this epithelial marker is ubiquitously expressed by mammary epithelial cells (20). The availability of these pictures greatly facilitated the interpretation of the gel data as it gave a rough estimate of the ratio of epithelial cells to stromal tissue. Only specimens with at least 80% tumor cells, evaluated by the combined H&E and CK19 stainings, were used for subsequent analysis. The proportion of cells was only used as inclusion criterion of selection of samples but not as a normalization parameter. Sample preparation for 2D PAGE from cell lines was performed as described previously (21).

**Tissue Interstitial Fluid (TIF) preparation**—Tissue interstitial fluid was recovered from tumor and normal samples following a previously published procedure (22). For analysis, 100 μl of TIF solution were lyophilized and subsequently solubilized in 0.1 ml lysis solution for 2D PAGE (18, 19).

**2D PAGE and 2D Western Immunoblotting**—2D PAGE (isoelectric focusing, IEF and nonequilibrium pH gradient electrophoresis, NEPHGE) and 2D gel Western blotting were performed as previously described (23). After running the second dimension, gels were placed in 7.5% acetic acid, 50% ethanol, and 0.05% formalin for 1 h, washed three times for 30 min each in 7.5% acetic acid, 10% ethanol, and stained with silver nitrate according to a procedure compatible with mass spectrometry (23). Silver stained gels were dried between cellulophane followed by scanning for comparative protein and MS analysis. 2D gel Western blotting was performed according procedure described elsewhere (24).

**Image Analysis**—2D gels were scanned and analyzed using the PDQUEST software package from BioRad (version 8.0.1). A comprehensive protein database of TNBC expression profile was prepared based on the analysis of 78 TNBC and using the gel of TNBC 22 as a master image. All identified protein spots selected for the analysis were added to the master image.

**Protein Spot Handling and Mass Spectrometry Analysis**—All detected protein spots were excised from silver stained dry gels followed by re-hydrating in water. Gel pieces were then detached from the cellulophane film and cut into 1 mm² pieces followed by “in-gel” digestion as previously described (25) followed by a MS analysis that has been reported previously using Anchor target 600 (22). We included in all cases a post-silver de-staining before in-gel tryptic digestion, thus additionally improving peptide recovery from the gel. MALDI-TOF-TOF data were acquired using an Ultraflex™ III 200 time-of-flight mass spectrometer (Bruker Daltonik, Germany) equipped with a Smart beam™ laser and a LIFT-TOF/TOF unit. Data acquisition and data processing were performed by the Flex Control 3.0 and Flex Analysis 3.0 software (Bruker Daltonik, Germany). All of the spectra were obtained using reflector positive mode with an acceleration voltage of 25 kV, reflector voltage of 26.38 kV and detection suppressed up to 450 Da. A total of 2000 shots in steps of 200 shots were added to one spectrum in the mass range of m/z 600–4000 using peak detection algorithm: SNAP (Sort Neat Assign and Place); S/N threshold: 3 and Quality Factor Threshold: 50.

**Spectral Analysis and Protein Identification**—Post-acquisition two step calibration was automatically performed in FlexAnalysis using standard peptide calibration mixture (Bruker Daltonics, Germany) for external calibration followed by an additional post-acquisition internal calibration step to obtain better mass accuracies. Ubiquitous presented auto-digested tryptic mass values visible in all the spectra were used for internal calibration. The background masses (matrix, metal adducts, tryptic peptides from contaminating alpha-keratins) were automatically subtracted from finally generated pick list and were excluded from the further analysis. Additionally, pairwise comparison of all analyzed spectra has been performed to remove irrelevant picks derived from putative contaminations. For protein identification, peptide masses were transferred to the BioTools 3.2 interface (Bruker Daltonik, Germany) to search in the National Center for Biotechnology nonredundant NCBIr (20110301) database using house MASCOT search engine (version 2.3.0.2, Matrix Science Ltd.). No restriction on the protein molecular mass and taxonomy was applied as a first step. A number of fixed (acylamide modified cystein, i.e. proponamide/carbamidomethylation) and variable modifications (methionine oxidation and protein N terminus acetylation) were included in the search parameters. The peptide tolerance did not exceed 30 ppm and a maximum of one trypsin missed cleavage was allowed. Protein identifications by peptide-mass fingerprinting were considered to be confident when the protein score of the hit exceed the threshold significance score of 65 (p < 0.05) and no less than six peptides were recognized.

If peptides match to multiple members of a protein family, and it was impossible to eliminate redundancy of unambiguous identification by applying manual search for unique isoform specific peptides, both family members were specified in the final table (Supplemental Tables S1 and S2). Whenever possible SwissProt accession numbers were assigned (UniProtKB/Swiss-Prot 55.3 (20247 human entries). Protein identification was confirmed by sequence information obtained from MS/MS analysis in “LIFT” mode. Whenever the protein score hit was close to the threshold significance score of 65, the LIFT analysis was performed as an additional mean to confirm the identity of the proteins identified by peptide-mass fingerprinting (PMF) using the same parameters as previously described (22).

**Enzyme-linked Immunosorbent Assay (ELISA)**—A sensitive and specific sandwich ELISA was developed using two of the Mage-A4 specific antibodies used in this study. The rab Ab 1982 (EP101638) rabbit polyclonal antibody was used for catching and the mouse monoclonal antibody to human Mage-A4 (CPTC-Mage-A4–1) was used for detection of the antigen as this combination provided the best signal-to-noise ratio. Immunoassay 96 MicroWell Solid Plates (Medisort™, Nunc, Denmark) were coated overnight at 4 °C with 100 μl per well of catching antibody solution (rab Ab 1982) 2 μg/ml in 100 mM bicarbonate/carbonate buffer (3.03 g Na2CO3 and 6.0 g NaHCO3 in 1000 ml distilled water, pH 9.6). The assay wells were rinsed five times with PBS buffer containing 0.05% (v/v) Tween20 (PBS-T). Wells were then treated with 200 μl of Protein-Free T20 (PBS) Blocking Buffer (Pierce, Thermo Scientific) for 1 h at 30 °C, and subsequently washed five times with washing buffer (PBS-T buffer) before use. One hundred microliter of diluted samples were added in triplicate to each well and incubated for 1 h at 30 °C. Every assay plate also contained a series of standards, consisting of eleven serial dilutions (1:2) of purified full length recombinant human Mage-A4 (ProSpec, Rehovot, Israel) in triplicate. Diluent for standards was PBS with 1% bovine serum albumin and the highest standard concentration was 50 ng/ml. Included on each plate were blank control wells, containing sample dilution buffer only. Before ELISA measurements, serum samples and
Compartmentation, and development times appropriate for each antibody allomark counterstained with hematoxylin. Standardization of the dilution, in-

Peroxidase complex (HRP conjugated goat anti-rabbit or anti-mouse body, followed by a suitable secondary antibody conjugated to a

Antigen was detected with a relevant primary anti-

Endogenous peroxidase activity quenched using 0.3% H2O2 in meth-

Tris, 1 mM EDTA) and heating them in a 750 W microwave oven for 10

Cultured in DMEM/10%FCS, were likewise formalin fixed and paraffin

Following surgery, fresh tissue blocks were immedi-

was kindly provided by G. Spagnoli.

mouse monoclonal antibody clone 57B (used at a dilution of 1:100),

by Eurogentec (Belgium) and was used at a dilution of 1:200. The

WRQPNEGSSSQE (aa78–92) raised against Mage-4 was generated

body EP101638 (rab Ab 1982) [N-term peptide immunogen: FTC-

which the concentration of Mage-A4 in samples was calculated.

Antibodies—A commercially available antibody against CK19 (mouse monoclonal; used at a dilution of 1:1000) was obtained from

Labvision-ThermoScientific. The CPTC-MageA4–1 hybridoma devel-

The CPTC-MageA4–1 hybridoma developed by the Clinical Proteomic Technologies for Cancer initiative was

Labvision-ThermoScientific. The CPTC-MageA4–1 hybridoma developed by the Clinical Proteomic Technologies for Cancer initiative was

obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The Uni-

ersity of Iowa, Department of Biology, Iowa City, IA 52242, and was used at a dilution of 1:1000. The rabbit polyclonal anti-antibody anti-

primary antibody were used as a negative control. For detection of immune complexes we

Recombinant Mage-A4 protein was added into one tube to a final concentration of 5 pg/µl giving app. 1:5 molar excess of blocking

Both tubes were incubated at room temperature for 1 h with agitation. Tandem sections of tissue or cell pellets paraffin blocks

were stained either with the blocked antibody or antibody alone and processed in parallel for antigen detection with an appropriate sec-

primary antibody. For detection of immune complexes we

A commercially available antibody against CK19 (mouse monoclonal; used at a dilution of 1:1000) was obtained from

Labvision-ThermoScientific. The CPTC-MageA4–1 hybridoma developed by the Clinical Proteomic Technologies for Cancer initiative was

obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The Uni-

IHC staining for each antibody (26–28). Normal rabbit or mouse sera instead of primary antibody were used as a negative control.

Blocking Experiments for IHC Validation—The appropriate amount of antibody was diluted in TBS buffer to the final volume needed for

staining of two section slides and divided equally into two tubes. Recombinant Mage-A4 protein was added into one tube to a final

concentration of 5 pg/µl giving app. 1:5 molar excess of blocking

peptide). Both tubes were incubated at room temperature for 1 h with

Antigen was detected with a relevant primary anti-

imputelines were matched using PDQUEST 8.0.1. Then, a master image was prepared that contained all the proteins spots present in the different images. To identify as many proteins
as possible we carried out a systematic computer assisted analysis of the 2D gels of the remaining TNBC samples. All matched proteins were identified by MALDI MS-MS as described in the Experimental Procedures section (The data associated with this manuscript may be downloaded from the ProteomeCommons.org Tranche network). Supplemental Tables S1 and S2 list all the proteins identified in the 78 TNBC patient cohort by either IEF (553 proteins) and/or NEPHGE (152 proteins) 2D PAGE analysis. Some polypeptides were identified both in IEF and NEPHGE gels and in addition, some proteins were identified in multiple spots, reflecting posttranslational protein processing. Consequently, the number of unique protein species we could identify in TNBCs was 523. It should be noted that in many cases the matching procedure was encumbered by confounding factors such as: the low abundance of some proteins, the fact that some proteins migrated close to a cluster of proteins, heterogeneity of tissue samples, as well as to the inherent variability in the gel runs. Consequently, it is likely that some proteins expressed by TNBCs escaped identification.

Inspection of the TNBC protein database, and comparison with proteomic data obtained from other breast cancer subtypes in our laboratory (23,24,30; this study), revealed a number of interesting candidate targets such as: tumor protein D52 (TPD52, IEF SSP# 8114, Supplemental Fig. S1), a protein frequently overexpressed in breast and other cancers (31) and a potential tumor antigen target for immunotherapy (32-34), D-3-phosphoglycerate dehydrogenase (PHGDH) (IEF SSP#2512; NEPHGE SSP# 2601, Supplemental Figs. S1 and S2, respectively), a protein involved in the serine biosynthetic pathway.
Proteomic Profiling of Triple-negative Breast Carcinomas

pathway that was recently identified in ER-negative breast cancer (35, 36), and melanoma-associated antigen 4 (Mage-A4) (Fig. 1 right hand panel and Supplemental Fig. S1; IEF SSP#8314), a protein that we selected for further analysis, as well as a number of other, potentially important, candidates that are currently being studied and will be reported in detail elsewhere. We also identified basal cytokeratin (CK) markers such as CK5 (multiple variants in NEPHGE SSP#2602, 3607, 3609, 4706, 5603, 6703, and 7603), CK6 (IEF SSP# 5501; multiple variants in NEPHGE SSP#3608, 4709, and 8601) and CK17 (IEF SSP# 7414) (Fig. 1, and Supplemental Figs. S1 and S2). The basal cytokeratins CK5/6 and CK17 have been proposed as potential IHC-based markers that can distinguish between basal and nonbasal tumor subtypes (37); as such the fact that we were able to identify these foreknown TNBC markers lend some support to the relevancy of our analysis.

Analysis of Mage-A4 Deregulation in Breast Cancer—
Selection and Specificity of Mage-A4 Antibodies—Mage-A4 is a cancer testis antigen (CTA), a protein whose expression is restricted to human germ line cells, but which is abnormally expressed in various types of cancer (38–42). A number of studies have previously established the expression of CTAs in breast tumors, and in some cases CTA expression was shown to be associated with hormone-receptor negative breast cancers (41, 43–49). However, these studies reported mostly on MAGE gene expression rather than protein levels or on the expression of Mage protein families rather than on specific proteins. The high degree of homology between different Mage proteins and the limited availability of anti-Mage antibodies recognizing only specific Mage family members, does not allow one to easily distinguish among Mage proteins; for example, the anti-Mage-A1 antibody 6C1 cross-reacts with Mage-A2, -A3, -A4, -A6, -A10, and -A12 (50).

To overcome the inherent difficulties associated with the extensive homology among the various Mage-A protein family members, we implemented a three-tier orthogonal technology approach based on the analysis of the same sample by 1) silver stained 2D PAGE coupled with MS-based identification of spots, 2) 2D Western blot, and 3) IHC using three different antibodies. This strategy combines the intrinsic sensitivity and cellular resolution of IHC, with the specificity of 2D Western and MS-based identification, and the overall protein analysis capability of 2D gels.

Several broad-spectrum vaccination strategies using cross-recognized epitopes, thus targeting various Mage protein family members, have been described (51, 52). But other more specific approaches targeting Mage-A4 also exist (53, 54). To analyze the specific expression of Mage-A4 protein we used a panel of three different antibodies: the first antibody was a rabbit polyclonal raised against a selected peptide of Mage-A4 (rab Ab 1982, raised against Mage-A4 aa78–92; Eurogentec). The second antibody was a monoclonal antibody (clone 57B) that was developed by Spagnoli and colleagues. This antibody was generated using Mage-A3 recombinant protein as immunogen and it recognizes an epitope (Mage-A3 aa16–31 region) that is identical in Mage-A2 and -A6, and differs by only 5, 3, and 1 residues in Mage-A1, -A4, and -A12, respectively (50), permitting cross-reactivity with Mage-A1, -A2, -A3, -A4, -A6, and -A12, as it was shown with cellular overexpression models (50, 55). Although at physiological levels of Mage-A protein family expression, the 57B mAb antibody (dilution 1:20) has shown specificity solely to Mage-A4, both in melanoma and nonsmall cell lung carcinoma tissue samples (55), thus suggesting a higher affinity of the antibody for Mage-A4, or that expression levels of this protein in tumor cells are higher than those of the other Mage-A proteins, any results obtained using this antibody should be interpreted with caution considering the potential for cross-reactivity. The third antibody we examined, was a mouse monoclonal antibody, CPTC-MageA4–1 developed by the U.S. NIH-Clinical Proteomic Technologies for Cancer Program (the epitope recognized by this antibody was not disclosed by the provider).

Determination of Antibody Specificity—Expression of CTAs in normal adult tissues is restricted to male germ cells in the testis. In malignancy, this pattern of regulation is disrupted, resulting in CTA expression in some tumors of various types. However, the spectrum of expression of CTAs in tumors of adult somatic tissues varies from individual tumor to individual tumor, with different CTAs being expressed differently in each case. Consequently, we tested the specificity of the our three antibodies by Western blotting using 2D gels of human normal testicular tissue, which expresses not only Mage-A4 (Fig. 2A), but also the full complement of potential cross-reacting Mage-A family proteins. As shown in Fig. 2B, all three antibodies detected various polypeptides of similar Mw (about 46kDa) in the testis extracts (Fig. 2B, black arrowheads), compatible with multiple post-translational modifications of the protein. This observation is congruent with published data identifying two phosphorylation sites (Ser90 and Ser99), and two ubiquitylation sites (Lys154 and Lys245) for Mage-A4 (56–58). The identity of the Mage-A4 protein spot corresponding to the major form recognized by all three antibodies (Fig. 2B, white arrows) was confirmed by MS in 2D gels of testis proteins (Fig. 2A, right hand panel). Despite an exhaustive analysis of all MS spectra generated from this area we did not find any hits (lower scores in Mascot search results) for other Mage-A proteins. In conclusion, with the one exception of the rab Ab 1982 antibody, which detected an additional smaller polypeptide (Fig. 2B, rab Ab 1982, gray arrow), the three antibodies showed comparable specificities. Interestingly, rab Ab 1982 did not detect this lower Mw polypeptide in multiple 2D blots from TNBCs samples (data not shown). It is possible that the lower Mw polypeptide corresponds to Mage-A5 (13 kDa, the smallest member of the Mage-A family) or to a smaller variant of the Mage-A4 protein present in testicular but not in breast tissue, as the existence of Mage-A4 isoforms under specific conditions has been previ-
Immunohistochemistry analysis of testicular biopsy specimens with normal spermatogenesis using the three Mage-A4 antibodies, showed that in all three cases Mage-A4 immunoreactivity occurred in spermatogonia, giving a characteristic "pearl-necklace" appearance (illustrated in Fig. 2C for rab Ab 1982). This observation reiterated the results previously reported for mAb 57B (55). In each case, this immunoreactivity could be blocked by pre-incubating the antibody with recombinant Mage-A4 protein (Fig. 2C, illustrated with recMage-A4/rab Ab 1982). As expected, samples exhibited strong nuclear and cytoplasmic Mage-A4 staining of spermatogonia and weak staining of spermatocytes. Multiple indirect immunofluorescence analysis of testis samples with the three antibodies confirmed that the antibodies have nearly identical staining patterns (data not shown). These data demonstrated that, under the conditions of the assays, the antibodies showed comparable specificity toward Mage-A4. All subsequent analyses were done primarily using the mAb 57B antibody, and results corroborated with the rab Ab 1982 and CPTC-MageA4–1 antibodies. For simplicity, only the data from the mAb 57B antibody are shown henceforth.

Evaluation of Antibody Specificity in Breast Carcinomas—To address the issue of antibody specificity in malignant samples, and given that some potential cross-reactivities may be expressed only under pathological conditions, we performed a comparative analysis of MAGE-A4 expression in breast tumor
Proteomic Profiling of Triple-negative Breast Carcinomas

biopsies and cell lines by 2D Western blotting followed by mass spectrometry analysis of the corresponding 2D gels. A number of Mage-A positive TNBC tissue biopsies were analyzed, and one representative example (DCTB T89) is shown in Fig. 3A. In addition, one cell line, the BRCA1-mutant triple-negative MDA-MB-436 cell line, which showed the highest expression of Mage-A4 protein among all lines we tested (data not shown), was also examined (Fig. 3B). As illustrated in Fig. 3, immunoblotting for Mage-A4 in T89 (Fig. 3A, mAb 57B) and MDA-MB-436 cell line (Fig. 3B, mAb 57B) was consistent with the identification of the proteins in corresponding 2D silver stained gels, both for T89 (Fig. 3A, spots 1 and 2 black arrows; Supplemental Table S3) and MDA-MB-436 (Fig. 3B, spots 1–5, black arrows, Supplemental Table S4). Additionally, 2D Western blot detection of purified recombinant human Mage-A4 protein (Fig. 3C, mAb57B) was also performed. The position of the mAb 57B immunoreactive spots on the gels of both breast carcinoma sample T89 and MDA-MB-436 cell line was matched to that of purified recombinant human Mage-A4 protein (compare Figs. 3A, B and C, mAb 57B 2D blots). The slightly different focusing of the Mage-A4 isoforms observed in the case of the purified recombinant protein is not surprising given the fact that a number of additional post-translational modifications are to be expected in mammalian cells and, additionally, the high complexity of tissue/cell lysates can affect IEF protein separation. Interestingly, although all visible spots in this area of the 2D PAGE gels were analyzed by MS (data not shown), we did not hit on any other Mage-A proteins (hits of lower scores in Mascot search results did not show any entries for other Mage-A proteins indicating an absence of peptides belonging to this group of proteins), which is in agreement with previous results showing lower expression level for the other Mage-A protein family members in breast cancer (47). Of note is the complete lack of cross-reactivity to any proteins from both breast tumor and MDA-MB-436 cell line (2D Western blots of full size are presented). No cross-reactivity was observed on the 2D Western blots of basic proteins (NEPHGE 2DPAGE, data not shown). The same results were obtained when rab Ab 1982 as well as CPTC-Mage-A4 antibodies were tested (data not shown).

The specificity of mAb 57B for IHC analysis of breast tissue was also examined by staining representative tissue specimens with antibody pre-incubated with recombinant Mage-A4 protein (Fig. 4). A number of Mage-A4 positive tumor biopsies were selected for this experiment and one representative example is shown in (Fig. 4A, T162). The pre-incubation of the antibody with the recombinant Mage-A4 protein before IHC effectively blocked immunostaining of T162, confirming the specificity of the antibody toward Mage-A4 in mammary tissue in IHC (Fig. 4A, compare mAb 57B with recMage-A4+mAb 57B panel). These results were also confirmed with the MDA-MB-436 cell line (Fig. 4B). MCF7, a breast tumor cell line that does not express Mage-A4 at detectable levels, did not display any immunoreactivity with mAb 57B (Fig. 4C) as expected. Taken together, these data demonstrate that the mAb 57B antibody is highly specific toward the Mage-A4 antigen in breast tumor samples ruling out a potential tissue-specific cross-reactivity confounder other than Mage-A protein family. Given the extensive homology among the various Mage-A protein family members, it is possible that samples with highly deregulated expression of a Mage-A protein other than -A4, could be immunopositive in IHC analysis with mAb 57B, and consequently incorrectly supposed to be positive for Mage-A4. However, the combination of orthogonal technology approaches to the analysis of the same sample we used, with IHC analysis by three different antibodies complemented with by silver stained 2D-PAGE
observed neither in a breast tumor section (A, compare B) MDA-MB-436, and (C) MCF7 cell lines. B) a representative FFPE primary breast tumor sample (T162), in (A) including 22 TNBC and 18 ER/PR+ cases (23, 25, 60). The results showed that 7 out of the 228 tumors expressed Mage-A4 (3.1% of all samples). The tumors expressing this protein belonged to two hormone receptor negative subtypes. Indeed, among the seven tumors expressing Mage-A4, four, DCTB T41, T58, T87, and T113 were of the ER/ PgR+/Her2− subtype (corresponding to 1.8% of all samples and 39% of the ER/ PgR− Her2− cases), and the remaining three, DCTB T22, T89 and T162 belonged to the triple negative subtype (corresponding to 1.3% of all samples and 13.6% of the TNBC cases). These data showed that in the DCTB 228 breast carcinoma sample cohort, expression of Mage-A4 was restricted to hormone-receptor negative tumors. As before, immunoreactivity for Mage-A4 (Fig. 5C, yellow arrow), was supported by MS-based identification of the protein in 2D gels (Fig. 5A, arrows indicate Mage-A4 spots) and 2D Western blot detection (Fig. 5B), verifying the specific expression of Mage-A4 in the ER/ PgR− Her2− tumors. Notably, we were able to identify two Mage-A4 spots in tumor DCTB 41 (Fig. 5A) confirming the existence of multiple post-translational modifications of the protein we had observed by 2D Western blots.

To confirm the high prevalence of Mage-A4 expression in ER/ PgR− Her2− breast tumors, we analyzed by IHC a panel of 30 additional retrospective ER/ PgR− Her2− breast tumor samples. We found that six samples (20%) expressed Mage-A4, showing that although the exact number of Mage-A4 expressing tumors may vary depending on the cohort, the prevalence of Mage-A4 in hormone-receptor negative disease is quite significant.

Because of inclusion criteria (see Experimental Procedures section), the DCTB patient cohort is biased toward high-grade tumors, a potential confounding factor of our analysis, particularly because previous studies showed that CTAs, in general, and Mage-A4, in particular, are associated with poorly differentiated histological phenotypes (45, 61). With this in mind and to validate our observations in an independent sample data set, we used a set of three commercial tissue microarrays (TMAs) comprising 210 cases (BRC1501, 1502, and 1503; Pantomics Inc., USA) for which hormonal and HER2 status is known. IHC analysis of the TMAs showed that seven cases expressed Mage-A4 (3.3%). Of these, five tumors were of the TNBC subtype, one was ER/ PgR− Her2−, and the remaining case was a micropapillary carcinoma (ER+/ PgR− Her2−) confirming that Mage-A4 was preferentially expressed in hormone-receptor negative breast cancer (six out of the seven positive cases; p < 0.001).

In brief, we found expression of Mage-A4 in roughly 3% of the cases present in the two all-inclusive sets of breast cancer samples examined, with 228 (DCTB cohort) and 210 cases (BRCA1501, 1502, and 1503 TMAs), respectively. Of these, 7 out of 7 cases, and 6 out of 7 cases, respectively, were hormone receptor negative (ER− PgR−). Conversely, when we examined two sets of hormone receptor negative subtypes, using TNBC (78 cases) and ER− PgR− Her2− (30 cases)
breast cancer cohorts, we found that 33 and 20% of cases, respectively, expressed Mage-A4. We concluded that expression of Mage-A4 protein was predominantly associated with hormone receptor negative breast cancers.

Several studies have previously reported an association between expression of CTAs and ER status in breast cancer (43–47). However, in the specific case of Mage-A4, no significant relationships with ER status were found in the two studies that explicitly addressed this question (46, 47). The study by Grigoriadis and colleagues refers to the combined analysis of nine publicly available gene expression datasets (47). ER status-specific MAGE-A4 gene expression for these breast tumor data sets showed a nonsignificant, median adjusted, \( p \) value of 0.314, indicating that MAGE-A4 gene expression is independent of ER-status. However, in one of the data sets underlying this study, the Desmedt dataset (62), MAGE-A4 did show estrogen specific expression \( (p = 0.00235) \). Moreover, in another data set underlying this study, the van de Vijver dataset, MAGE-A4 expression showed a significant correlation with the basal subgroup \( (p < 0.001) \) (47). Basal-like tumors are of a higher grade and predominantly ER-negative. In brief, although the combined analysis of nine publicly available gene expression datasets by Grigoriadis and colleagues found no association between MAGE-A4 expression and ER-status, two of the constituent datasets did display this association.

In the case of the work by Bandić et al. (46) expression of Mage-A4 was studied by IHC using the 57B mAb antibody undiluted, and as such the results are more relatable to our own. In this study, the authors examined the expression of Mage-A4 by IHC on archival paraffin-embedded samples of breast cancer tissue from 81 patients and found that Mage-A4 immunoreactivity was not significantly associated with ER status (46). However, because the patients included in the study had to comply with a set of selection criteria (all patients had T1 to T3, N0 to N1, M0 tumors and underwent postoperative adjuvant radiotherapy), there is an inherent bias in the cohort. Moreover, Mage-A4 expression did show a trend, albeit nonsignificant, toward association with ER status \( (p = 0.082) \). In conclusion, the results we present here and the fact that several studies have reported an association between expression of CTAs and ER status in breast cancer (43–47) indicate that it is likely that expression of Mage-A4 protein is also associated with hormone receptor negative breast cancer.

Detection of Mage-A4 Protein in Interstitial Fluid and Patient Sera—As part of the breast cancer biomarker early detection program within DCTB we have systematically collected tumor interstitial fluid (TIF) from portions of freshly dissected DCTB tumor samples (22, 63). TIFs collected from the seven DCTB cases that expressed Mage-A4 were analyzed by 2D Western blotting. We found Mage-A4 was present in TIFs derived from tumors bearing a high percentage of Mage-A4 positive cells. This is illustrated in Fig. 6 for DCTB 89, a triple negative tumor that exhibited high-level expression of Mage-A4 as determined by 2D Western blotting (Fig. 6A, DCTB T89 panel) and generalized tumoral cell expression evaluated by IHC (Fig. 6B; DCTB N89 panel). As expected, no immunoreactivity for Mage-A4 was observed in normal tissue (Fig. 6B; DCTB N89 panel). Externalization of Mage-A4 was coupled with cellular expres-
tion of the protein, and not solely specific for TNBCs, as we could also detect Mage-A4 in interstitial fluids from ER−/PgR−/Her2+ tumors that expressed Mage-A4 (data not shown).

In view of these results, we decided to develop an ELISA assay for detection of Mage-A4 protein to address the question of whether Mage-A4 protein could be detected in human sera of patients bearing breast tumors. Given that we had extensively established the specificity of a set of three different antibodies recognizing Mage-A4, we decided to establish a sandwich ELISA assay for detecting Mage-A4 using a combination of these antibodies. The rab Ab 1982 and CPTC-MageA4–1 antibody combination showed the best performance in ELISA assays in exploratory studies and was chosen for further validation. The minimum reproducibly detectable level of Mage-A4 protein by this assay was determined to be 0.5 pg/μl. We performed spike and recovery experiments using low (10 pg/μl), medium (25 pg/μl), and high (40 pg/μl) spike concentrations. We applied the ELISA assay to the analysis of a set of 12 interstitial fluid samples collected from patients within the DCTB cohort of 228 carcinoma samples, and for which we had sufficient biomaterial available. Of these, two samples, TIF58 and TIF113, both of the ER−/PgR−/Her2+ subtype, were obtained from tumors that expressed Mage-A4. The remaining TIFs were collected from tumors that did not express Mage-A4 (DCTB 46, 51, 52, 56, 57, 74, and 78). As an additional control for possible sample heterogeneity we used interstitial fluid from three matched normal samples (NIFs 46, 51, 56) because normal glandular cells do not express Mage-A4 (illustrated in Fig. 6B, DCTB T89 panel). We found that one single sample (TIF from DCTB 58) presented increased levels of Mage-A4 protein (10.04 pg/μl; Fig. 7A, left hand axis). The presence of Mage-A4 in this TIF was confirmed by 2D Western blot (Figs. 7B, DCTB T58 panel) and IHC (Fig. 7C). We were unable to detect Mage-A4 in TIF collected from DCTB 113, even though immunostaining of the tumor showed that it was positive for Mage-A4. Because Mage-A4 immunostaining was quite heterogeneous in this tumor (data not shown), it is possible that the tissue piece we extracted TIF from did not express this protein at sufficient levels to allow detection.
Proteomic Profiling of Triple-negative Breast Carcinomas

Although we had access to a very limited number of sera from DCTB patients, we used our sandwich-ELISA assay to analyze the 16 sera available. Of the sera examined (DCTB 15, 19, 20, 26, 31, 40, 42, 43, 46, 47, 51, 53, 55, 58, and 59) only one case was from a patient bearing a Mage-A4 positive tumor (DCTB 58), and this was also the only sample showing detectable levels of serum Mage-A4 (3.62 pg/μl) (Fig. 7A, right hand axis). These results indicate that Mage-A4 protein is detectable in sera of breast cancer patients. Unfortunately, the limited number of samples available to us did not allow us to address critical issues, such as the influence of tumor size and intrinsic biological factors affecting the ability of Mage-A4 of being detected in blood (for example Mage-A4 shedding rates from tumor cells) (64). Given the potential high specificity of any well-validated detection assay based on Mage-A4, because no normal cells express Mage-A4 other than testes and placenta so that background levels of the protein are minimal, this protein has been suggested as a useful biomarker for early detection of cancer, and in some cases such as head-and-neck squamous cell carcinoma, hepatocellular carcinoma, and ovarian carcinoma, ELISA assays for detection of elevated serum Mage-A4 were successfully established (65–69) and harbor some promise. In the case of breast cancer, however, the low frequency of Mage-A4 positive tumors (3–3.3%) we showed here makes its use as a screening marker for early detection of cancer, and in some cases such as head-and-neck squamous cell carcinoma, hepatocellular carcinoma, and ovarian carcinoma, ELISA assays for detection of elevated serum Mage-A4 were successfully established (65–69) and harbor some promise. However, additional studies in well-defined case/control cohorts using validated high sensitivity assays will be required to provide level 1 evidence for the feasibility of using Mage-A4 as monitoring marker.

The detection of MageA4 in the sera of patients would allow the implementation of a valuable clinical blood marker. The detection of Mage-A4 in the sera of patients evidence for the feasibility of using Mage-A4 as monitoring marker. Studies in well-defined case/control cohorts using validated high sensitivity assays will be required to provide level 1 evidence for the feasibility of using Mage-A4 as monitoring marker.

Acknowledgments—We thank Ewa Raipert-De Meyts for kindly providing samples. We would also like to thank Kitt Christensen, Sofia Svensson, Dorte Holm, Lene Jørgensen, and Anni Handesten for expert technical assistance.

* This work was supported by the Danish Cancer Society through the budget of the Research Center, and by grants from the "Race against Breast Cancer" foundation, the John and Birthe Meyer Foundation, Novo Nordisk Foundation, and the Lisa and Gudmund Jørgensen Foundation.

†† To whom correspondence should be addressed: Irina Gromova and José Moreira, Danish Cancer Society Research Center and Danish Centre for Translational Breast Cancer Research, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen Ø, Denmark.
E-mails: iig@cancer.dk and jomo@sund.ku.dk, respectively.

§§ These authors contributed equally to this work.

In memoriam: Dr. med. Fritz Rank - Consultant of Pathology at Copenhagen University Hospital.

REFERENCES

1. Anderson, W. F., Chu, K. C., Chatterjee, N., Brawley, O., and Brinton, L. A. (2011) Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J. Clin. Oncol. 19, 18–27
2. Baselga, J., Perez, E. A., Pienkowski, T., and Bell, R. Adjuvant trastuzumab: a milestone in the treatment of HER2-positive early breast cancer Oncologist 11 Suppl 1, 4–12, 2006
3. Chu, K. C., and Anderson, W. F. (2002) Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res. Treat. 74, 199–211
4. Pohlmann, P., Rath, T., Cagnon, H., and Menaun, R. (2009) Resistance to trastuzumab in breast cancer. Clin. Cancer Res. 15, 7479–7491
5. Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E. Jr., Davidson, N. E., Tan-Chiu, E., Martin, S. P., Pinkston, E. M., Swain, S. M., Pisanski, T. M., and Feulner, M. C. Vogel, V. G., Wischak, D. W., Yotkov, G., Jenkins, R. B., Brown, A. M., Dakhil, S. R., Mamounas, E. P., Lingle, W. L., Klein, P. M., Linn, G. M., and Wolmark, N. (2005) Trastuzumab plus chemotherapy for operable HER2-positive breast cancer. N Engl. J. Med. 353, 1673–1684
6. Badve, S., Dabbs, D. J., Schnitt, S. J., Baehner, F. L., Decker, T., Eusebi, V., Fox, S. B., Ichihara, S., Jaquemin, J., Lakhan, S. R., Palacios, J., Rakha, E. A., Richardson, A. L., Schmitt, F. C., Tan, P. H., Tse, G. M., Weigel, B., Ellis, I. O., and Reis-Filho, J. S. (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 24, 157–167
7. Anders C., and Carey L. A. (2009) Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin. Breast Cancer 9, S73–81
8. Yamamoto, Y., and Iwase, H. (2010) Clinicopathological features and treat-
22. Gromov, P., Gromova, I., Bunkenborg, J., Cabezon, T., Moreira, J. M., Celis, J. E., Trentemølle, S., and Gromov, P. (2004) Gel-based proteomics: a new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. Science 254, 1643–1647.

15. Parmigiani, R. B., Bettoni, F., Vibranovski, M. D., Lopes, M. H., Martins, N., Hunter, T., Shotton, D., Simons, K., and Small, J. V., eds) Vol. 4, genes in women with relapsing invasive ductal breast cancer: retrospective, validation strategy for triple-negative breast cancer. Clin. Cancer Res. 15, 988–1002.

26. Dunstan, R. W., Wharton, K. A. Jr., Quigley, C., and Lowe, A. (2011) The use of immunohistochemistry for biomarker assessment—can it compete with other technologies? Toxicol. Pathol. 39, 988–1002.

27. Taylor, C. R., and Levenson, R. M. (2006) Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II. Histopathology 49, 411–424.

28. Walker, R. A. (2008) Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment I. Histopathology 49, 406–410.

29. Iwash, S., Ellis, P., and Tutt, A. (2011) Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Curr. Opin. Oncol. 23, 566–577.

30. Celis, J. E., Gromov, P., Cabezón, T., Moreira, J. M., Friis, E., Jirström, K., Liombart-Bosch, A., Timmermans-Wielenga, V., Rank, F., vGromova, I., Llombart-Bosch, A., Chim, L., Wagner, G., Asara, J. M., Brugge, J. S., Cantley, L. C., and Byrne, J. A. (2000) Tumor-specific shared antigenic peptides recognized by human T cell clones: a gene family capable of eliciting humoral response in cancer patients. Proc. Natl. Acad. Sci. U.S.A. 103, 18066–18071.

31. Taylor, C. R., and Levenson, R. M. (2006) Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment I. Histopathology 49, 411–424.

32. Locasale, J. W., Grassian, A. R., Melman, T., Lyssiotis, C. A., Mattaini, K. R., Bass, A. A., Heffron, G., Metallo, C. M., Munar, T., Shab, H., Sasaki, M., Bagnardi, V., Spagnolli G. C., Old L. J., and Byrne, J. A. (2006) The hD52 (TPD52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosomes Cancer 29, 48–57.

33. Locasale, J. W., Grassian, A. R., Melman, T., Lyssiotis, C. A., Mattaini, K. R., Bass, A. A., Heffron, G., Metallo, C. M., Munar, T., Shab, H., Sasaki, M., Bagnardi, V., Spagnolli G. C., Old L. J., and Byrne, J. A. (2006) The hD52 (TPD52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosomes Cancer 29, 48–57.

34. Locasale, J. W., Grassian, A. R., Melman, T., Lyssiotis, C. A., Mattaini, K. R., Bass, A. A., Heffron, G., Metallo, C. M., Munar, T., Shab, H., Sasaki, M., Bagnardi, V., Spagnolli G. C., Old L. J., and Byrne, J. A. (2006) The hD52 (TPD52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosomes Cancer 29, 48–57.
Proteomic Profiling of Triple-negative Breast Carcinomas

Metzler, D., Wang, J., Coombes, K. R., Gätje, R., Hanker, L., Solbach, A., Ahrl, A., Holtrich, U., Rody, A., and Kaufmann, M. (2011) Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. *Eur. J. Cancer* doi:10.1016/j.ejca.2011.06.025

45. Chen, Y. T., Ross, D. S., Chiu, R., Zhao, X. K., Chen, Y. Y., Lee, P., Hoda, S. A., Simpson, A. J., Old, L. J., Caballero, O., and Neville A. M. (2011) Multiple cancer/testis antigens are preferentially expressed in hormone-nonsensitive breast cancers. *PLoS One* 18, e17876

46. Bandić, D., Juretić, A., Sarcević, B., Separović, V., Kuznjedžil-Tiljak, M., Hudolin, T., Spagnoli, G. C., Covic, D., and Samija, M. (2006) Expression and possible prognostic role of Mage-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. *Croat. Med. J.* 47, 32–41

47. Grigoriadis, A., Caballero, O. L., Hoek, K. S., da Silva, L., Chen, Y. Y., Shin, S. J., Jungbluth, A. A., Miller, L. D., Clouston, D., Cebron, J., Old, L. J., Lakhani, S. R., Simpson, A. J., and Neville, A. M. (2009) CT-X antigen expression in human breast cancer. *Proc. Natl. Acad. Sci. U.S.A.* 106, 13493–13498

48. Chen, Y. T., Hsu, M., Lee, P., Shin, S. J., Mhaweck-Faucigella, P., Odunsi, K., Altorki, N. K., Song, C. J., Jin, B. Q., Simpson, A. J., and Old, L. J. (2009) Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. *Int. J. Cancer* 124, 2893–2898

49. Adams, S., Greeder, L., Reich, E., Shao, Y., Fosina, D., Hanson, J., Nasdello, O., Singh, B., Spagnoli, G. C., Demaria, S., and Jungbluth, A. A. (2011) Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprophylaxis. *Cancer Immunol. Immunother.* 60, 999–1007

50. Rimoldi, D., Salvi, S., Schultz-Thater, E., Spagnoli, G. C., and Cerottini, J. C. (2000) Anti-Mage-3antibody 57B and anti-Mage-1 antibody 6C1 can be used to study different proteins of the Mage-A family. *Int. J. Cancer* 86, 749–751

51. Graff-Dubois, S., Faure, O., Gross, D. A., Alves, P., Scardino, A., Chouaib, S., Lemonnier, F. A., and Kosmatopoulos, K. (2002) Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by Mage-A1, A2, A3, A4, A6, A10, and A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. *J. Immunol.* 169, 575–580

52. Kawada, J., Wada, H., Isobe, M., Gnjatic, S., Nishikawa, H., Jungbluth, A. A., Okazaki, N., Uenaka, A., Nakamura, Y., Fukushima, S., Mizuno, N., Saika, T., Ritter, E., Yamasaki, M., Miya, H., Ritter, G., Murphy, R., Venhaus, R., Pan, L., Old, L. J., Doki, Y., and Nakayama, E. (2012) Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. *Int. J. Cancer* 130, 584–592

53. Cruz, C. R., Gerdemann, U., Leen, A. M., Shafer, J. A., Ku, S., Tzou, B., Horton, T. M., Sheehan, A., Copeland, A., Younes, A., Rooney, C. M., Heslop, H. E., and Bollard, C. M. (2011) Improving T cell therapy for relapsed EBV negative Hodgkin's Lymphoma by targeting upregulated Mage-A4. *Cancer Res.* 71, 7058–7066

54. Shirakura, Y, Mizuno, Y, Wang, L, Imai, N, Amaike, C, Sato, E, Ito, M, Roepstorff, P., Bolund, L, Omrtto, T, Brünner, N, Overgaard, J, Sandelin, D, Blichert-Toft, M, Mouridsen, H, and Rank, F. E. (2003) Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. *Mol. Cell. Proteomics* 2, 369–377

55. Kavalar, R, Sarcevic, B, Spagnoli, G,C, Separovic, V, Samija, M, Terracciano, L, Heberer, M, and Juretic, A (2001) Expression of Mage tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study. *Virchows Arch.* 439, 127–131

56. Desmedt, C, Piette, F, Loi, S, Wang, Y, Lallemand, F, Haibe-Kains, B, Viale, G, Delorenzi, M, Zhang, Y, Saghatelian d'Assignies, M, Bergh, J, Liderneau, R, Ellis, P, Harris, A,L, Klijn, J G M, Foekens, J A, Cardoso, F, Piccart M J, Buyse, M, Sotiriou, C, and on behalf of the TRANSBIG Consortium (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. *Clin. Cancer Res.* 13, 3207–3214

57. Celis, J. E., Gromov, P., Cabezón, T., Moreira, J. M., Ambartsumian, N, Sandelin, K, Rank, F, and Gromova, I. (2004) Proteomic characterization of the interstitial fluid perfusing the breast tumour microenvironment: a novel resource for biomarker and therapeutic target discovery. *Mol. Cell. Proteomics* 3, 327–344

58. Hori, S. S., and Gambhir, S. S. (2011) Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. *Sci. Transl. Med.* 3, 109–116

59. Iwamoto, O, Nagao, Y, Shichijo, S, Eura, M, Kameyama, T, and Itoh, K (1997) Detection of Mage-4 protein in sera of patients with head-and-neck squamous-cell carcinoma. *Int. J. Cancer* 70, 287–290

60. Kawagoe, H, Yamada, A, Matsumoto, H, Ito, M, Ushijima, K, Nishida, T, Yakuishi, M, and Itoh, K (2000) Serum Mage-4 protein in ovarian cancer patients. *Gynecol. Oncol.* 76, 336–339

61. Shichijo, S, Tsunoue, R, Kubo, K, Kuramoto, T, Tanaka, Y, Hayashi, A, and Itoh, K (1995) Establishment of an enzyme-linked immunosorbent assay (ELISA) for measuring cellular Mage-4 protein on human cancers. *J. Immunol. Methods* 186, 137–149

62. Tsuzurahara, S, Sata, M, Iwamoto, O, Shichijo, S, Kojiro, M, Takinaka, K, and Itoh, K (1997) Detection of Mage-4 protein in sera of patients with hepatitis-C virus-associated hepatocellular carcinoma and liver cirrhosis. *Jpn. J. Cancer Res.* 88, 915–918

63. Shichijo, S, Hayashi, A, Takamori, S, Tsunoue, R, Hoshino, T, Sakata, M, Kuramoto, T, Oizumi, K, and Itoh, K (1995) Expression in human tissue of the interstitial fluid perfusing the breast tumour microenvironment: a novel resource for biomarker and therapeutic target discovery. *Mol. Cell. Proteomics* 3, 327–344

64. Gabos, Z, Tomers, J, Ghosh, S, Hansen, J, Deschênes, J, Sabri, S, and Abdulkarim, B (2010) The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. *Breast Cancer Res. Treat.* 124, 187–194

65. Kyndt, M, Sørensen, F B, Knudsen, H, Overgaard, M, Nielsen, H M, Overgaard, J, and Danish Breast Cancer Cooperative Group (2008) Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. *Cancer Res.* 68, 1419–1426

66. Zaky, S Y, Lund, M M, May, K A, Godette, K D, Beiter, J J, Holmes, L R, O'Regan, R M, Yu, E S, Yu, D S, and Landry, J C (2011) The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy. *Ann. Surg. Oncol.* 18, 2588–2585

MCP

MOLECULAR & CELLULAR PROTEOMICS

AASBM